Form 4: Cero Therapeutics Holdings Director Acquires Stock Options
SEC Form 4 Filing
Michael Byrnes, a director of Cero Therapeutics Holdings, acquired stock options for 17,923 shares on March 4, 2025.
Summary
- Michael Byrnes, a director of Cero Therapeutics Holdings, Inc., filed a Form 4.
- The form reports a transaction that occurred on March 4, 2025.
- Byrnes acquired stock options for 17,923 shares of common stock at an exercise price of $1.43.
- These options vest over time, with 50% vesting on the twelve-month anniversary of the grant date and the remaining portion subject to performance conditions.
- The options expire on March 3, 2035.
- Following the transaction, Byrnes directly owns 17,923 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, which is neutral in sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which can be a signal of their confidence in the company's future prospects.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 03/04/2025 | Date of transaction: Michael Byrnes acquired stock options. |
| 03/06/2025 | Date of signature on the Form 4 filing. |
| 03/03/2035 | Expiration date of the stock options. |
Keywords
Form 4, Stock Options, Director, CERO, Cero Therapeutics Holdings, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.